FDA gives pump to support right heart its blessing

Candace Stuart | | Cardiovascular Business | Heart Failure

The FDA granted Abiomed a Humanitarian Device Exemption for a percutaneous single-access heart pump for patients who develop right heart failure or decompensation.

The approval applies to the Impella RP System, which is designed to provide right heart support. Acute right heart failure or decompensation can occur after patients receive a left ventricular assist device (LVAD) implant, experience an MI, or undergo a heart transplant or open-heart surgery.

The Impella RP System assists with flow and pressure by providing up to four liters per minute of hemodynamic support. It can be used in pediatric and adult patients for up to 14 days.

The FDA based its approval on results from the RECOVER RIGHT trial, which evaluated the safety and probable benefit of the system in 30 patients with right ventricular failure. The patients either developed right ventricular failure within 48 hours after LVAD implantation or after cardiotomy shock or post-acute MI shock.  

The overall survival rate was 73 percent at 30 days (83.3 percent in the LVAD group and 58.3 percent in the cardiotomy/post-acute MI shock group).  

The FDA is requiring Danvers, Mass.-based Abiomed to conduct one post-approval study that enrolls at least 30 adult patients and one that enrolls at least 15 pediatric patients treated with the device.

Candace Stuart, Contributor

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."